Hutchmed (china) Share Discussion Threads

[nerdofsteel] 22/7/2017 08:56

Big Pharma licensing deal coming I think

[nerdofsteel] 18/7/2017 15:57

Lots and lots of news due

[nerdofsteel] 17/7/2017 16:21

2 weeks today until interims

[nerdofsteel] 15/7/2017 07:38

Decision by Lilly not made public so I assume they have deferred for a while until they analyse the data and consider how the drug may compete with their other one

[nerdofsteel] 13/7/2017 08:11

We still have all this material news to come this year:-

Savolitinib Phase III in c-Met-driven PRCC - will include large up-front Milestone payment $5m) - COMPLETE

Epitinib Phase II/III in first-line patients with EGFR-mutant NSCLC with brain metastasis

Savolitinib Phase III in combination with Tagrisso® (osimertinib) in second-line NSCLC (T790M-/c-Met+)

Fruquintinib NDA in China by mid 2017 - Milestone (submitted June 12th) - COMPLETE

$40m dividend due from Commercial JV by end June

Savolitinib PRCC Possible U.S. NDA under BT designation in 2017 (pending FDA questions)

Lilly decision by end May on whether to commercialise Fruq outside of China (decision can be delayed for a further year if they wish, but will have to pay more) - PENDING

[nerdofsteel] 13/7/2017 08:10

"The relative ignorance in the US about the company’s potential makes it a great investment right now"

This article offers a great perspective for those looking to invest for the long term, and by that I mean 5 years +

And it is the U.S share price that mainly drives the UK share price now, as volumes are usually bigger on NASDAQ

[nerdofsteel] 07/7/2017 08:52

Yesterdays news that BGNE (which IPO'd on NASDAQ just before us) has done a deal with Celgene demonstrates that big U.S Biopharmas are keen to do deals with late stage Biotechs like us.

Watch this space for a deal here - we have 100% global rights at the moment to Sulfatinib, Epitinib and other drugs which Big Phrama are probably looking at with increasing interest. They get potential BT with these and can leverage low cost development. These assets are due for launch in the next few years and are either First or Best in Class. I think a deal similar to the Celgene-Beigene one announced yesterday is on the cards here.

And I note Celgene took a direct 5.9% stake in Beigene delivering immediate Shareholder value day 1.

[nerdofsteel] 29/6/2017 09:59

Fantastic news today on Phase III PRCC Savolitinib

This is a GLOBAL trial - extremely important and this will be pushed through very quickly

The U.S market will loe this and continue to drive the price

I continue to buy

[haydock] 29/6/2017 09:14

A nice quiet bulletin board, very few private Investors
Very busy company, good newsflow.

[nerdofsteel] 20/6/2017 07:04

indeed! A nice quiet bulletin board, very few private Investors and the herd will hopefully never arrive because this is a very very long term investment. That said, it has and will continue to deliver very very significant value to those Shareholders who are prepared to stay invested for many years - no day traders here...

[haydock] 19/6/2017 09:28

Facinating: 2nd largest share on AIM, nil interest, when all systems go !
Must say something about bb's.
Certainly the usual negative posters have not featured, a greatly refreshing change.
Onward & upwards.

[nerdofsteel] 13/6/2017 07:54

From today's Times

Drug development is all about pushing boundaries, and that is the case at Hutchison China Meditech, or Chi-Med, as it is known. The Shanghai-based pharmaceuticals company, whose biggest shareholder is Li Ka-shing’s CK Hutchison Group, is on the verge of launching the first mainstream drug developed in China from design to production.

Fruquintinib, a potential treatment for various cancers, has been in development for about a decade.

The drug passed a major milestone in March when Chi-Med unveiled positive phase III trial results for patients with advanced colorectal cancer, which was presented at the American Society of Clinical Oncology’s annual gathering in Chicago last week.

Yesterday, as expected, Chi-Med submitted its application to market the drug to the China Food and Drug Administration, triggering a $4.5 million milestone payment from Eli Lilly, the US pharmaceutical group and Chi-Med’s partner on the drug. The regulatory process takes about 12 months but there are hopes Chi-Med will secure it sooner, given the attention that the drug has received and its significance to the international standing of China’s pharmaceutical industry.

If Chi-Med launches the drug next year, as the market is forecasting, the opportunity is significant.

Colorectal is the second most common cancer type in China, with about 380,0000 new cases a year, according to the national central cancer registry. Analysts at Stifel are pencilling in sales of $300 million to $400 million a year in China.

The company also has a marketing and distribution platform which sells prescription and over-the-counter medicines and provides a launch pad to take its drug pipeline to market.

Globally there are about 1.4 million new cases a year and the price would probably be higher in the US, where Chi-Med is also carrying out clinical trials and is targeting phase III results in a couple of years.
With eight drug candidates in 30 clinical trials, including savolitinib, a cancer treatment being developed with Astrazeneca, the bulls have been grabbing the stock by the horns. Shares have rallied about 60 per cent over the past 12 months and remain close to March’s peak.
MY ADVICE Buy
WHY Shares have eased off record highs, but the pipeline is slowly delivering

Here's the link to the article for those with a subscription:-

hxxps://www.thetimes.co.uk/article/chi-med-on-way-to-break-out-of-china-k7x6kf9zf

[nerdofsteel] 12/6/2017 08:49

Our first NDA submitted - let's hope the China FDA approve in similar timescales to Icotinib (10 months) - then we will get a nice revenue and net income increase in 2018

[nerdofsteel] 25/5/2017 09:41

Not long now for this bit of news



If Eli Lilly take up the option for global Fruquintinib, that culd/should be material to the valuation of Chi-Med when you realise forecast peak sake outside of China for all indications is $1.8bn p.a. and Chi-Med will get circa 11% of that

[nerdofsteel] 21/5/2017 13:34

Not long now for this bit of news



If Eli Lilly take up the option for global Fruquintinib, that culd/should be material to the valuation of Chi-Med when you realise forecast peak sake outside of China for all indications is $1.8bn p.a. and Chi-Med will get circa 11% of that

[nerdofsteel] 23/4/2017 16:56

Seller cleared, but sector down in last few days and the election announcement caused a currency re-alignment which knocked off a few percent

Lots of news due

I look forward to the AGM again, on Thursday in London, where there will be a great opportunity to meet a number of key new Non Execs

[nerdofsteel] 19/4/2017 10:51

1. Big rise in sterling in the UK as a result of election announcement means UK shares were out of sync with US ADR price and were adjusted downwards

2. Biotech sector drop in the U.S yesterday

Great opportunity to buy more shares at a cheaper price IMO

[haydock] 19/4/2017 10:49

Look at the charts for clues, turning down.
Hopefully rounded top, after a few days.

[reptile3] 19/4/2017 09:25

No news to support this. Only 1.72k shares traded so far today but the share price is down £1.75 = 5.76% on the FT website. Someone mentioned Tesaro and Genmab as comparators but they are down 0.09% and up 1.1% respectively so it's not a sector problem. Mm's playing games?

[hamsterdam] 19/4/2017 08:39

Any reason behind today's big drop?

[nerdofsteel] 12/4/2017 12:38

Big Pharma is expensive but I think they will deploy any newly raised funds wisely.

They have a clear vision and a strategy they are executing against.

One aspect they are not too happy about is giving away rights to Savolitinib and Frquintinib a few years ago in order to raise cash for further development.

If I had to guess I would say any new cash could be used to buy out Eli Lilly on Frquintinib if Lilly choose not to exercise their right to take it global. That decision has to be made any day now, or they can defer for a year and pay a higher milestone fee.

Whatever happens we have a lot of news due on numerous fronts very soon and the AGM on the 27th of course. Always an interesting meeting.

[miti 1000] 12/4/2017 10:55

DBADVFN ,

HCM have always made it clear they will raise more cash as they progress to more phase 3 trials. They are certainly not an ordinary aim outfit. No alarms have been rung by that filing.

[nerdofsteel] 11/4/2017 14:05

All this still to come in the next few weeks and months

Savolitinib Phase III in c-Met-driven PRCC - will include large up-front Milestone payment

Epitinib Phase II/III in first-line patients with EGFR-mutant NSCLC with brain metastasis

Savolitinib Phase III in combination with Tagrisso® (osimertinib) in second-line NSCLC (T790M-/c-Met+

Fruquintinib NDA in China by mid 2017 - Milestone due

$40m dividend due from Commercial JV by end June

Savolitinib PRCC Possible U.S. NDA under BT designation in 2017

Lilly decision by end May on whether to commercialise Fruquintinib outside of China (decision can be delayed for a further year if they wish, but will have to pay more)

[nerdofsteel] 04/4/2017 07:15

But they have a great track record of using cash and funds to create value, they won't be raising funds to just keep the lights on. Pharma is a very expensive long term business but the potential rewards for late stage companies are large - look at Genmab and Tesaro as examples of where we will be in the next 2 or 3 years

[dbadvn] 03/4/2017 18:55

Nerdofsteel,

I agree; however the way they have handled it does make them look like an ordinary little AIM company , and will certainly ring alarm bells where none is needed.

One week emphasisiing that they have two years cash to analyst briefings and the next issuing an SEC filing authorising a placing will put a large dent in the confidence that analysts place in the management and question future statements.

They need to ensure that they differentiate themselves by having clear , consistent and timely information to both US and UK investors.

Poorly handled listing , inconsistent communication of fund raising intention = two strikes. Three and I'm out.